- Home
- NAGE vs MLYS Comparison
NAGE vs MLYS Comparison
Compare NAGE & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAGE
- MLYS
- Stock Information
- Founded
- NAGE 1999
- MLYS 2019
- Country
- NAGE United States
- MLYS United States
- Employees
- NAGE N/A
- MLYS N/A
- Industry
- NAGE Medicinal Chemicals and Botanical Products
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- NAGE Health Care
- MLYS Health Care
- Exchange
- NAGE Nasdaq
- MLYS Nasdaq
- Market Cap
- NAGE 861.0M
- MLYS 890.6M
- IPO Year
- NAGE N/A
- MLYS 2023
- Fundamental
- Price
- NAGE $9.82
- MLYS $36.31
- Analyst Decision
- NAGE Strong Buy
- MLYS Strong Buy
- Analyst Count
- NAGE 3
- MLYS 6
- Target Price
- NAGE $17.00
- MLYS $42.60
- AVG Volume (30 Days)
- NAGE 803.7K
- MLYS 2.6M
- Earning Date
- NAGE 10-30-2025
- MLYS 11-10-2025
- Dividend Yield
- NAGE N/A
- MLYS N/A
- EPS Growth
- NAGE N/A
- MLYS N/A
- EPS
- NAGE 0.22
- MLYS N/A
- Revenue
- NAGE $116,303,000.00
- MLYS N/A
- Revenue This Year
- NAGE $28.46
- MLYS N/A
- Revenue Next Year
- NAGE $21.65
- MLYS N/A
- P/E Ratio
- NAGE $44.84
- MLYS N/A
- Revenue Growth
- NAGE 35.90
- MLYS N/A
- 52 Week Low
- NAGE $3.16
- MLYS $8.24
- 52 Week High
- NAGE $14.69
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- NAGE 50.03
- MLYS 83.59
- Support Level
- NAGE $9.16
- MLYS $35.00
- Resistance Level
- NAGE $9.77
- MLYS $39.20
- Average True Range (ATR)
- NAGE 0.38
- MLYS 2.56
- MACD
- NAGE 0.03
- MLYS 1.67
- Stochastic Oscillator
- NAGE 59.88
- MLYS 88.85
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.